KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Get an alert when KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£21M
USD 27,714,000
+1.1% vs 2023
Net assets
£327M
USD 436,836,000
+25.4% vs 2023
Employees
309
+22.6% vs 2023
Profit before tax
-£27M
USD -36,152,000
-316.6% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
2 PSCs ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £91,593,033 | £174,311,131 | £311,750,766 | +78.8% | |
| Operating profit | £25,187,262 | £23,419,302 | £61,818,793 | +164% | |
| Profit before tax | £8,242,506 | £12,478,134 | -£27,025,492 | -316.6% | |
| Net profit | -£137,073,335 | -£10,528,519 | -£32,289,004 | -206.7% | |
| Cash | — | £20,501,607 | £20,717,650 | +1.1% | |
| Total assets less current liabilities | — | £46,016,297 | £91,253,644 | +98.3% | |
| Net assets | — | £260,407,416 | £326,557,524 | +25.4% | |
| Equity | — | £260,407,416 | £326,557,524 | +25.4% | |
| Average employees | — | 252 | 309 | +22.6% | |
| Wages | — | £43,709,468 | £63,671,898 | +45.7% | |
| Directors' remuneration | — | £1,274,192 | £2,837,702 | +122.7% |
Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Operating margin | 27.5% | 13.4% | 19.8% | |
| Net margin | -149.7% | -6.0% | -10.4% | |
| Return on capital employed | — | 50.9% | 67.7% | |
| Gearing (liabilities / total assets) | — | 33.8% | 24.8% | |
| Current ratio | — | 2.33x | 2.99x | |
| Interest cover | 11.08x | 10.26x | 26.37x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- US GAAP
- Reporting scope
- Consolidated group
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC · parent
- Kiniksa Pharmaceuticals Corp. 100%
- Primatope Therapeutics, Inc. 100%
- Kiniksa Pharmaceuticals (UK) Ltd. 100%
- Kiniksa Pharmaceuticals, Ltd. 100%
- Kiniksa Pharmaceuticals (Germany) GmbH 100%
- Kiniksa Pharmaceuticals (France) SARL 100%
- Kiniksa Pharmaceuticals, Gmbh 100%
Significant events
- “A principal decision taken by the Board in the year ended 31 December 2024 was the approval of the Redomiciliation, pursuant to which Kiniksa International was formed and the Group changed the principal place of incorporation of its parent company from Bermuda to the United Kingdom.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
11 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BARRY, Douglas, Mr. | Secretary | 2025-09-18 | — | — |
| BAKER, Felix James, Dr | Director | 2024-06-27 | Mar 1969 | American |
| BIGGAR, Stephen Richard | Director | 2024-06-27 | Sep 1970 | American |
| BOYD, Meta Cantey | Director | 2024-10-04 | Dec 1979 | American |
| COLE, Gordon Bradley | Director | 2024-06-27 | Jan 1956 | American |
| LEVY, Richard Steven | Director | 2024-06-27 | May 1957 | American |
| MALLEY, Thomas Robert | Director | 2024-06-27 | Dec 1968 | American |
| MCCAIN, Tracey Lorene | Director | 2024-06-27 | Nov 1967 | American |
| PATEL, Sanjiv | Director | 2024-04-09 | Jul 1969 | American |
| POPOVITS, Kimberly Johnston | Director | 2024-06-27 | Dec 1958 | American |
| QUART, Barry Davd, Dr. | Director | 2024-06-27 | Jan 1957 | American |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ZEYLIKMAN, Madelyn | Secretary | 2024-04-09 | 2025-09-18 |
| MEGNA, Michael | Director | 2024-04-09 | 2024-06-27 |
| MOAT, Ross Michael | Director | 2024-04-09 | 2024-06-27 |
| RAGOSA, Mark | Director | 2024-04-09 | 2024-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Baker Bros. Advisors Lp | Corporate entity | Shares 25–50% | 2024-06-28 | Ceased 2025-07-01 |
| Sanjiv Patel | Individual | Voting 25–50% | 2024-06-28 | Active |
| Mr Felix James Baker | Individual | Shares 25–50% | 2024-06-27 | Active |
| Kiniksa Pharmaceuticals, Ltd. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-04-09 | Ceased 2024-06-28 |
Filing timeline
Last 20 of 61 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-04-30 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-23 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-23 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-04-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-03-13 | SH01 | capital | Capital allotment shares | |
| 2026-02-23 | SH01 | capital | Capital allotment shares | |
| 2026-01-19 | SH01 | capital | Capital allotment shares | |
| 2025-12-16 | SH01 | capital | Capital allotment shares | |
| 2025-12-03 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-12-03 | SH01 | capital | Capital allotment shares | |
| 2025-11-04 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-11-04 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-10-10 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 6
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.